Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
Hosted on MSN2mon
Turns Out That Biosimilars Do Impact Biologic Drug Costs"Compared with biosimilars, uptake of new generic drugs is often rapid, averaging 66% of the market share during the first year after brand-name market exclusivity ends." Adalimumab ought to be ...
#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...
Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback